Listed

HeartBeam, Inc.

BEATWNasdaqCIK 1779372HealthcareFiscal year ends Dec 31

Revenue is not reported in this company’s XBRL financial statements.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.10Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349121.Report this figure+33.3% on a year earlier
  • Free cash flow−$3.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349121. Derived: 6-month figure less the 3-month figure.Capital expenditure: $249.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349121. Derived: 6-month figure less the 3-month figure.Report this figure−1.2% on a year earlier

Last eight quarters

Full statements
Diluted EPS−$0.10, Q2 FY2026
Free cash flow−$3.6m, Q2 FY2026
HeartBeam, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$knot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.19)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001193125-25-280112.Report this figurenot reported (Diluted EPS not reported)(0.18)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221565.Report this figure(0.15)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349121.Report this figure(0.15)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001193125-25-280112.Report this figurenot reported (Diluted EPS not reported)(0.12)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221565.Report this figure(0.10)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349121.Report this figure
Free cash flow$k(3,409)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001193125-25-280112. Derived: 9-month figure less the 6-month figure.Capital expenditure: $103.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001193125-25-280112. Derived: 9-month figure less the 6-month figure.Report this figure(4,152)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104080. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104080. Derived: 12-month figure less the 9-month figure.Report this figure(4,477)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221565.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001193125-26-221565.Report this figure(3,547)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349121. Derived: 6-month figure less the 3-month figure.Capital expenditure: $102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349121. Derived: 6-month figure less the 3-month figure.Report this figure(3,242)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001193125-25-280112. Derived: 9-month figure less the 6-month figure.Capital expenditure: $82.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001193125-25-280112. Derived: 9-month figure less the 6-month figure.Report this figure(3,322)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104080. Derived: 12-month figure less the 9-month figure.Capital expenditure: $416.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104080. Derived: 12-month figure less the 9-month figure.Report this figure(3,856)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$3.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221565.Capital expenditure: $246.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001193125-26-221565.Report this figure(3,591)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349121. Derived: 6-month figure less the 3-month figure.Capital expenditure: $249.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349121. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Diluted EPS−$0.62, FY2025
Free cash flow−$14.6m, FY2025
HeartBeam, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(1.03)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-16, accession 0001779372-23-000006.Report this figure(1.59)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-20, accession 0001779372-24-000002.Report this figure(0.72)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-13, accession 0001628280-25-012614.Report this figure(0.73)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-104080.Report this figure(0.62)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-104080.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)(9.9)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$9.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-20, accession 0001779372-24-000002.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-20, accession 0001779372-24-000002.Report this figure(12.3)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$12.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001628280-25-012614.Capital expenditure: $256.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-13, accession 0001628280-25-012614.Report this figure(14.7)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104080.Capital expenditure: $201.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104080.Report this figure(14.6)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104080.Capital expenditure: $600.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104080.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding HeartBeam, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.6m2,137,512Added+939,719
BlackRock, Inc.2026-06-30$740.9k987,837Added+89,516
CORSAIR CAPITAL MANAGEMENT, L.P.2026-06-30$684.4k912,500New+912,500
Bleichroeder LP2026-06-30$468.8k625,000New+625,000
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$359.6k479,386Added+102,174
Smith Salley Wealth Management2026-06-30$275.7k367,647Unchanged
UBS Group AG2026-06-30$224.2k298,917Reduced−36,272
VANGUARD FIDUCIARY TRUST CO2026-06-30$206.1k274,818Added+124,756
Sigma Planning Corp2026-06-30$185.8k247,700Added+115,150
Beacon Pointe Advisors, LLC2026-06-30$185.3k247,058Reduced−400

Recent filings

All 271 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

HeartBeam, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-1421:01 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001213900-26-090241
2026-08-1320:30 ETSCHEDULE 13D/AOwnership report, active investor, amended0001213900-26-089158
2026-08-1320:02 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-349121
2026-08-0622:16 ET8-K/A5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001213900-26-085822
2026-08-0320:15 ET8-K5.07 Shareholder vote results0001213900-26-084622
2026-07-0220:15 ET8-K3.01 Delisting notice0001213900-26-074979
2026-06-2421:28 ET8-K5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-26-071605
2026-06-2220:15 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001213900-26-070628
2026-06-1821:00 ETDEF 14AProxy statementPeriod 2026-06-180001193125-26-276053
2026-05-1320:02 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-221565

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 12, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1779372
Tickers
BEATW, BEAT
Exchange
Nasdaq
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.